On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Stratec Biomedical AG Gemini. This instrumentation change is necessary as Bio-Rad is discontinuing service on our existing QuickStep instrumentation.
Although the Immucor assay and sample requirements will remain the same, the package insert has been modified to state the assay is specific to the Stratec Gemini instrument. The new package insert, assay history list, and platform history list will be available on the CTS website on 04/29/19.
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
On June 13, 2019, the new CTS Laboratory Information System was successfully implemented in Cha...
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...
As the US coast prepares for Hurricane Florence to make landfall, we have received importan...
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...
On August 9, 2019, the new CTS Laboratory Information System was successfully implemented in St...